MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molina Healthcare Inc (MOH) does not present a strong buy opportunity at this time. The company's financial performance is weak, with significant declines in net income and EPS, and analysts have mixed to negative sentiments with multiple price target reductions. While technical indicators show some stability, there are no strong positive catalysts or trading signals to justify a buy for a beginner investor with a long-term focus.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 64.015, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 151.058 and 155.396, with support at 137.016 and 132.678.
NULL identified. No recent news or significant positive developments.
Weak Q4 financials with a significant drop in net income (-163.75%) and EPS (-171.17%). Analysts have lowered price targets, citing concerns about Medicaid and Medicare pressures, as well as volatility in revenue and expense accruals.
In 2025/Q4, revenue increased by 8.34% YoY to $11.375 billion. However, net income dropped to -$160 million (-163.75% YoY), EPS fell to -$3.16 (-171.17% YoY), and gross margin declined to 10.51% (-23.79% YoY).
Analysts have mixed to negative views. Recent price target changes include increases by BofA (to $152) and UBS (to $151), but significant reductions by Mizuho (to $180 from $220), Morgan Stanley (to $128 from $158), and others. Concerns center around Medicaid and Medicare cost pressures and poor Q4 performance.
